U.S. Markets closed

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1300-0.0700 (-1.67%)
At close: 4:00PM EDT

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard
Suite 110
Newark, CA 94560
United States
510 293 8800
http://www.cymabay.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Sujal A. ShahPres, CEO & Director820.57kN/A1973
Dr. Charles A. McWherterSr. VP & Chief Scientific Officer597.89kN/A1955
Mr. Paul T. QuinlanGen. Counsel, Chief Compliance Officer & Corp. Sec.578.82kN/A1963
Mr. Daniel MenoldVP of Fin.N/AN/A1970
Mr. Ken BoehmSr. VP of HRN/AN/AN/A
Mr. Patrick J. O'MaraSr. VP of Bus. Devel.N/AN/A1961
Dr. Robert L. MartinSr. VP of Manufacturing & Nonclinical Devel.N/AN/A1962
Ms. Klara A. Dickinson-EasonChief Regulatory & Quality Assurance OfficerN/AN/A1968
Ms. Becki FiliceSr. VP of Portfolio & Product LeadershipN/AN/A1961
Dr. Dennis D. Kim M.B.A., M.D., MBAChief Medical OfficerN/AN/A1970
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Corporate Governance

CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.